Skip to main content
. Author manuscript; available in PMC: 2013 Jul 1.
Published in final edited form as: Free Radic Biol Med. 2012 May 8;53(1):160–171. doi: 10.1016/j.freeradbiomed.2012.05.001

Table 1.

The measured oxylipin baseline in CF sputa samples a.

Sample Name TXB2 PGF2a PGE2 11-HETE PGE1 20-COOH-LTB4 20-OH-LTB4 LTB4 6-trans-LTB4 5-oxo-ETE 5-HEPE LTB5 12-HETE 12-oxo-ETE 12-HEPE 9-HODE 9-oxo-ODE 8-HETE 15-oxo-ETE 15(S)-HETrE 13-HODE 20-HETE
Pathway
COX
5-LOX
12-LOX
15-LOX
CYP4A/4F
Substrates
AA
DGLA
AA
EPA
AA
EPA
LA
AA
DGLA
LA
AA
1 342 535 601 168 79.1 3760 1380 319 236 7480 239 99.8 371 837 21.7 941 305 92.6 49.5 220 820 488
2 88.5 188 103 11.7 30.9 157 103 87.3 31.0 153 12.6 0.00 3070 3520 209 262 82.6 40.5 76.8 200 912 31.8
3 155 69.6 116 84.2 29.7 560 252 253 193 338 24.4 0.00 8580 11100 287 3260 3900 258 739 1010 6700 185
4 1340 410 1060 187 70.5 9740 1500 2630 238 3440 107 23.0 10800 8430 479 770 350 108 274 448 2730 195
5 11800 344 750 207 60.6 1240 293 201 95.8 747 22.0 N.D. 7010 5090 141 1030 293 278 507 667 2320 2250
6 864 524 745 829 180 2910 733 979 2730 57.3 267 N.D. 174000 47900 4700 3070 2340 1160 419 944 14400 657
7 1080 321 630 208 43.3 899 236 274 53.3 71.3 N.D. N.D. 10200 4450 590 969 357 163 296 227 2780 531
8 691 372 1220 128 120 726 95.2 170 89.1 553 20.1 N.D. 10100 4980 314 557 201 41.7 111 224 1420 411
9 145 202 191 95.3 29.6 3500 396 1610 63.9 4240 119 41.1 1280 924 115 746 225 110 97.7 181 2490 344
10 219 32.9 254 13.0 8.35 1440 416 644 47.1 1630 27.1 N.D. 3110 4400 168 196 165 21.3 130 127 397 281
11 6840 152 228 22.4 24.9 1490 156 118 165 1130 0.00 N.D. 15600 20600 375 196 36.2 85.5 69.6 96.8 786 471
12 2330 32.9 85.3 N.D. 9.07 3940 514 788 152 1280 76.9 12.1 5510 4800 329 788 212 54.4 56.4 141 4460 N.D.
13 562 418 536 131 130 5690 737 5340 1370 23500 930 108 8540 7010 282 807 428 219 370 993 2380 335
14 629 786 561 316 49.8 4240 2240 2810 226 3990 259 70.7 852 836 23.1 766 403 269 259 420 1850 667
15 619 154 390 82.2 26.6 3080 2050 1590 70.9 2870 46.5 15.9 1820 4020 15.4 390 164 61.6 215 154 1520 51.6
16 101 133 67.3 817 N.D. 7.42 48.0 280 49.6 2300 128 N.D. 1310 777 115 2700 328 1210 670 3360 10700 845
17 1230 699 935 298 67.0 13700 3230 6750 574 13700 417 156 3860 3720 174 1790 572 353 406 799 5490 657
Mean 1710 316 498 212 56.4 3360 1240 1630 376 3970 159 31.0 15600 7850 490 1130 610 266 279 601 3650 494
SD 3050 226 361 249 48.4 3610 1830 1960 686 6090 232 48.2 41000 11400 1100 978 994 359 214 783 3800 514
Patient # CYP 2C/2J CYP2C/2J+sEH Multi-enzymes
AA
LA
EPA
LA
LA
EPA
8(9)-EpETrE 12(13)-EpOME 9(10)-EpOME 5,6-DiHETE 12,13-DiHOME 9,10-DiHOME 9,12,13-TriHOME 9,10,13-TriHOME LXA4 Resolvin E1
1 21.4 54.4 61.6 275 N.D. N.D. N.D. N.D. N.D. 522
2 69.8 49.1 47.2 4.09 N.D. N.D. N.D. N.D. N.D. N.D.
3 309 184 81.0 80.6 54.9 24.4 445 103 N.D. N.D.
4 38.9 60.0 16.7 97.5 19.3 29.2 472 48.3 N.D. 758
5 259 68.3 61.0 27.8 379 299 11400 622 N.D. 48.6
6 4090 474 222 1650 76.4 37.2 3260 150 N.D. 49.5
7 66.3 69.5 107 12.1 59.0 27.7 1830 215 N.D. 280
8 84.5 N.D. 19.9 27.3 579 706 19700 711 N.D. N.D.
9 11.3 58.3 39.7 80.9 78.7 34.7 1370 162 N.D. N.D.
10 99.9 8.27 N.D. 39.0 86.8 7.21 867 95.2 N.D. N.D.
11 163 8.09 N.D. 33.7 68.9 66.1 2920 379 N.D. 106
12 224 47.2 N.D. 196 29.7 9.55 784 37.7 N.D. N.D.
13 77.9 36.8 N.D. 1560 67.3 N.D. 391 57.3 N.D. 173
14 30.3 N.D. 61.0 234 74.2 43.0 4200 113 N.D. N.D.
15 22.4 99.0 41.4 278 12.2 N.D. 435 149 N.D. 67.0
16 6.66 34.3 42.3 135 8.68 2.47 499 97.0 N.D. N.D.
17 251 0.79 85.1 412 77.8 70.8 2340 209 N.D. 1040
Mean 343 73.6 52.1 303 52.1 35.7 3540 332 N.D. 338
SD 970 113 54.7 504 415 308 7770 379 N.D. 358
a

All the concentrations are in pmol/g.

N.D. Not detected.